FIGURE 2: BRCA1 methylation and risk of ovarian cancer. Forest plot illustrating the odds ratio (OR) for ovarian cancer (all subtypes), non-serous, serous non-high grade and high grade serous ovarian cancer (HGSOC) related to BRCA1 promoter methylation, derived from the initial study population and the validation cohort in the recent publication by Lønning et al. [131]. The odds ratios (ORs) were based on analyses of 925 cases and 1688 controls (initial study) and 607 cases and 1914 controls (validation study). Reprint of original figure, with permission from Annals of Internal Medicine.

• Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, deFazio A, McNeish LA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL, et al. (2018). Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9: 3970. doi: 10.1038/s41467-018-05564-z